So, everybody’s chasing AI stocks. Fine. Whatever. It’s a bubble. I’m telling you, it’s a bubble. But then you get these analysts, these so-called analysts, saying, “Oh, look at Viking Therapeutics!” Viking Therapeutics. Like I’m supposed to be excited about Viking Therapeutics. It’s a biotech company. They make…drugs. Groundbreaking. And now they’re supposed to be the next big thing? It’s just… exhausting.
They’re saying the stock is “undervalued.” Undervalued according to whom? Some algorithm? Some kid in a basement? Yahoo! Finance? Please. Their “average price target” is $92.72. That’s 181% upside. Right. Like that’s actually going to happen. It’s always “potential.” Everything is “potential” until it isn’t. And then you’re stuck with the stock, and it’s just sitting there, mocking you.
The Weight of It All
Apparently, they’re working on weight-loss drugs. Weight-loss drugs! As if that’s solving any real problems. It’s just treating the symptom, not the cause. People eat too much! It’s not complicated! And now we need a drug for that? It’s a society that rewards instant gratification. I mean, it’s a booming market, sure. Obesity is a “serious, highly prevalent condition.” You don’t say. And of course, all the big pharmaceutical companies are jumping in. It’s like a feeding frenzy. It’s just… predictable.
Viking Therapeutics is “a fairly small player.” Which is a polite way of saying they’re probably going to get crushed by the giants. But they have this candidate, VK2735. Sounds like a robot. They’re doing clinical trials. 78 weeks! Who has 78 weeks to wait for a weight-loss drug? I have things to do. They’re also working on an oral version. Because apparently, taking a pill is too much effort. It’s just… the level of convenience we demand now is astounding.
Risk Tolerance? More Like Risk Ignorance
So, what does it take for this thing to actually hit that $92.72 target? “Strong phase 3 results.” Of course. But the bar keeps getting higher. Every drug company claims their drug is the best. It’s just marketing. And now they need to prove it’s better than the other drugs. It’s a never-ending cycle. And gastrointestinal issues? Seriously? You’re trying to help people lose weight, but you give them diarrhea? What’s the point? It’s just shifting the problem around.
If everything goes perfectly, maybe, just maybe, the stock will go up. But even then, it might not hit that lofty target. They’ll record “solid revenue growth.” Wonderful. But what happens if the results aren’t “excellent?” The stock tanks. And then they’ll try to “regroup and recover.” As if that’s easy. It’s just… the optimism in this market is infuriating. There’s “substantial upside potential,” they say. And “plenty of risk.” No kidding. It’s always a risk. Everything is a risk.
So, invest accordingly. Which means, probably don’t. Or if you do, be prepared to lose it all. Because that’s how these things usually work. It’s a game, and the house always wins. And frankly, I have better things to worry about. Like finding a decent parking spot. Now that’s a real problem.
Read More
- Building 3D Worlds from Words: Is Reinforcement Learning the Key?
- Gold Rate Forecast
- Securing the Agent Ecosystem: Detecting Malicious Workflow Patterns
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Wuthering Waves – Galbrena build and materials guide
- The Best Directors of 2025
- Games That Faced Bans in Countries Over Political Themes
- TV Shows Where Asian Representation Felt Like Stereotype Checklists
- 📢 New Prestige Skin – Hedonist Liberta
- SEGA Sonic and IDW Artist Gigi Dutreix Celebrates Charlie Kirk’s Death
2026-03-09 17:02